View ValuationAmbu 향후 성장Future 기준 점검 4/6Ambu (는) 각각 연간 23.6% 및 10.7% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 24.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 13.5% 로 예상됩니다.핵심 정보23.6%이익 성장률24.41%EPS 성장률Medical Equipment 이익 성장13.5%매출 성장률10.7%향후 자기자본이익률13.46%애널리스트 커버리지Good마지막 업데이트12 May 2026최근 향후 성장 업데이트공시 • Aug 22Ambu A/S Revises Financial Guidance for the Year 2024/25Ambu A/S revised financial guidance for the year 2024/25. For the period, the company revised organic revenue growth: 12% to 14% (previously 11% to 14%) and EBIT margin b.s.i.: 13% to 15%.공시 • Jan 10Ambu A/S Raises Financial Guidance for the Year 2024/25Ambu A/S provided financial guidance for the year 2024/25. The outlook for organic revenue growth is set to 11-14% (previously 10-13%) and for EBIT margin before special items to 13-15% (previously 12-14%).공시 • Jan 30+ 1 more updateAmbu A/S Maintains Earnings Guidance for the Full-Year 2023/24Ambu A/S maintained earnings guidance for the Full-Year 2023/24. For the period,company expects Organic revenue growth of 7%-10%, EBIT margin before special items of 8%-10%.공시 • Nov 09Ambu A/S Provides Earnings Guidance for the Full-Year 2023/24Ambu A/S provided earnings guidance for the full-year 2023/24 . For the year, the company expected total organic revenue growth 7-10% for the 2023/24 financial year, compared to 7.6% in 2022/23; EBIT before special items is expected to be 8-10%, compared to 6.3% in 2022/23.공시 • Sep 01+ 1 more updateAmbu A/S Narrows Earnings Guidance for the Full-Year 2022/23Ambu A/S narrowed earnings guidance for the full-year 2022/23. For the year, the company expected organic revenue growth guidance to 6%-8%, previously 5%-8%; EBIT margin before special items: 5-6% (maintained as per 10 July 2023).공시 • Jul 12Ambu A/S Raises Earnings Guidance for the Full-Year 2022/2023Ambu A/S raised earnings guidance for the full-year 2022/2023. For the year, company expects EBIT margin before special items to 5% - 6% (previously 3% - 5%).모든 업데이트 보기Recent updates공시 • Nov 07Ambu A/S announces Annual dividend, payable on December 08, 2025Ambu A/S announced Annual dividend of DKK 0.4100 per share payable on December 08, 2025, ex-date on December 04, 2025 and record date on December 05, 2025.공시 • Oct 01Ambu A/S, Annual General Meeting, Dec 02, 2026Ambu A/S, Annual General Meeting, Dec 02, 2026.공시 • Sep 30+ 3 more updatesAmbu A/S to Report Q1, 2026 Results on Feb 04, 2026Ambu A/S announced that they will report Q1, 2026 results on Feb 04, 2026공시 • Aug 22Ambu A/S Revises Financial Guidance for the Year 2024/25Ambu A/S revised financial guidance for the year 2024/25. For the period, the company revised organic revenue growth: 12% to 14% (previously 11% to 14%) and EBIT margin b.s.i.: 13% to 15%.공시 • Jan 10Ambu A/S Raises Financial Guidance for the Year 2024/25Ambu A/S provided financial guidance for the year 2024/25. The outlook for organic revenue growth is set to 11-14% (previously 10-13%) and for EBIT margin before special items to 13-15% (previously 12-14%).공시 • Nov 08Ambu A/S Proposes DividendThe Board of Directors of Ambu A/S proposed a dividend of DKK 0.38 per share of nominally DKK 0.50 so that a dividend in the total amount of DKK 102 million be paid out of the net profit for the year, corresponding to 43% of the group's net profit, whereas the remaining part of the net profit be carried forward to next year.Reported Earnings • Nov 06Full year 2024 earnings released: EPS: kr.0.88 (vs kr.0.65 in FY 2023)Full year 2024 results: EPS: kr.0.88 (up from kr.0.65 in FY 2023). Revenue: kr.5.39b (up 13% from FY 2023). Net income: kr.235.0m (up 40% from FY 2023). Profit margin: 4.4% (up from 3.5% in FY 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.공시 • Oct 01+ 3 more updatesAmbu A/S, Annual General Meeting, Dec 03, 2025Ambu A/S, Annual General Meeting, Dec 03, 2025.공시 • Sep 30Ambu A/S to Report Q1, 2025 Results on Jan 30, 2025Ambu A/S announced that they will report Q1, 2025 results on Jan 30, 2025Reported Earnings • Sep 01Third quarter 2024 earnings released: EPS: kr.0.50 (vs kr.0.19 in 3Q 2023)Third quarter 2024 results: EPS: kr.0.50 (up from kr.0.19 in 3Q 2023). Revenue: kr.1.38b (up 16% from 3Q 2023). Net income: kr.134.0m (up 163% from 3Q 2023). Profit margin: 9.7% (up from 4.3% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.Reported Earnings • May 15Second quarter 2024 earnings released: EPS: kr.0.54 (vs kr.0.06 in 2Q 2023)Second quarter 2024 results: EPS: kr.0.54 (up from kr.0.06 in 2Q 2023). Revenue: kr.1.37b (up 15% from 2Q 2023). Net income: kr.144.0m (up kr.129.0m from 2Q 2023). Profit margin: 11% (up from 1.3% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 18% per year whereas the company’s share price has fallen by 19% per year.Reported Earnings • Jan 31First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: kr.1.25b (up 11% from 1Q 2023). Net income: kr.92.0m (up 318% from 1Q 2023). Profit margin: 7.3% (up from 1.9% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany.공시 • Jan 30+ 1 more updateAmbu A/S Maintains Earnings Guidance for the Full-Year 2023/24Ambu A/S maintained earnings guidance for the Full-Year 2023/24. For the period,company expects Organic revenue growth of 7%-10%, EBIT margin before special items of 8%-10%.공시 • Dec 14Ambu A/S Elects Shacey Petrovic as Vice Chair of Board of DirectorsAmbu A/S at its Annual General Meeting held on December 13, 2023, elected Shacey Petrovic as Vice Chair of the Board of Directors.공시 • Nov 18Ambu A/S Announces Henrik Ehlers Wulff Not to Run for Re-Election for Board of DirectorsAmbu A/S at the Annual General Meeting to be held on 13 December 2023 Henrik Ehlers Wulff has decided not to run for re-election for Board of Directors.공시 • Nov 09Ambu A/S Provides Earnings Guidance for the Full-Year 2023/24Ambu A/S provided earnings guidance for the full-year 2023/24 . For the year, the company expected total organic revenue growth 7-10% for the 2023/24 financial year, compared to 7.6% in 2022/23; EBIT before special items is expected to be 8-10%, compared to 6.3% in 2022/23.공시 • Oct 12+ 1 more updateAmbu A/S Appoints Henrik Skak Bender as Member of the Executive Management, Effective 1 January 2024Ambu A/S has appointed Henrik Skak Bender as the company’s new Chief Financial Officer and member of the Executive Management, effective 1 January 2024. Henrik succeeds Thomas Frederik Schmidt, who will step down, effective 31 December 2023. During the past 20 years, Henrik has worked at leading international companies, such as was Audiology, Urban Partners, McKinsey & Co and A.P. Moller-Maersk. At the hearing aid company, was Audiology, he served as CFO and Head of Integration, leading the finance, IT, legal and procurement functions. Prior to that, he served as CFO at Widex, where he was responsible for developing and executing the company’s growth and transformation strategy, together with the rest of the management team. Most recently, Henrik joins from the asset management company, Urban Partners, where he serves as a member of the executive management, leading the company to grow from a Nordic player with EUR 6bn in assets under management in 2020 to a Northern European player with EUR +20bn in assets under management. At Urban Partners, Henrik held a position as Partner and COO, where he focused on driving and scaling a wide range of functions, including Investor Relations, Finance, IT and Sustainability.공시 • Sep 30+ 4 more updatesAmbu A/S to Report Q2, 2024 Results on May 14, 2024Ambu A/S announced that they will report Q2, 2024 results on May 14, 2024공시 • Sep 01+ 1 more updateAmbu A/S Narrows Earnings Guidance for the Full-Year 2022/23Ambu A/S narrowed earnings guidance for the full-year 2022/23. For the year, the company expected organic revenue growth guidance to 6%-8%, previously 5%-8%; EBIT margin before special items: 5-6% (maintained as per 10 July 2023).Reported Earnings • Sep 01Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: kr.1.20b (up 5.9% from 3Q 2022). Net income: kr.51.0m (up 82% from 3Q 2022). Profit margin: 4.3% (up from 2.5% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany.공시 • Jul 12Ambu A/S Raises Earnings Guidance for the Full-Year 2022/2023Ambu A/S raised earnings guidance for the full-year 2022/2023. For the year, company expects EBIT margin before special items to 5% - 6% (previously 3% - 5%).Reported Earnings • May 03Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr.1.19b (up 6.0% from 2Q 2022). Net income: kr.15.0m (down 91% from 2Q 2022). Profit margin: 1.3% (down from 16% in 2Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 21% per year whereas the company’s share price has fallen by 20% per year.Reported Earnings • Feb 08First quarter 2023 earnings released: EPS: kr.0.09 (vs kr.0.08 in 1Q 2022)First quarter 2023 results: EPS: kr.0.09 (up from kr.0.08 in 1Q 2022). Revenue: kr.1.13b (up 9.8% from 1Q 2022). Net income: kr.22.0m (up 10.0% from 1Q 2022). Profit margin: 1.9% (in line with 1Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.공시 • Feb 07Ambu A/S Provides Earnings Guidance for the Financial Year of 2022-2023Ambu A/S provided earnings guidance for the financial year of 2022-2023. For the year, the company expected organic revenue growth is 5% to 8%.Board Change • Nov 22High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Susanne Larsson was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 16Full year 2022 earnings releasedFull year 2022 results: Revenue: kr.4.44b (up 11% from FY 2021). Net income: kr.93.0m (down 62% from FY 2021). Profit margin: 2.1% (down from 6.2% in FY 2021). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 9% per year.공시 • Oct 01+ 3 more updatesAmbu A/S to Report Q3, 2023 Results on Aug 31, 2023Ambu A/S announced that they will report Q3, 2023 results on Aug 31, 2023Buying Opportunity • Sep 17Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 1.1%. The fair value is estimated to be €11.74, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has declined by 21%. Revenue is forecast to grow by 26% in 2 years. Earnings is forecast to grow by 74% in the next 2 years.Reported Earnings • Aug 26Third quarter 2022 earnings released: EPS: kr.0.11 (vs kr.0.24 in 3Q 2021)Third quarter 2022 results: EPS: kr.0.11 (down from kr.0.24 in 3Q 2021). Revenue: kr.1.13b (up 16% from 3Q 2021). Net income: kr.28.0m (down 55% from 3Q 2021). Profit margin: 2.5% (down from 6.4% in 3Q 2021). Over the next year, revenue is forecast to grow 16%, compared to a 7.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.Valuation Update With 7 Day Price Move • Aug 06Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to €9.30, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 37x in the Medical Equipment industry in Germany. Total loss to shareholders of 33% over the past three years.Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorated over the past weekAfter last week's 25% share price decline to €9.36, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Total loss to shareholders of 22% over the past three years.공시 • May 20+ 1 more updateAmbu A/S Reaffirms Earnings Guidance for the Fiscal Year 2021/22Ambu A/S reaffirmed earnings guidance for the fiscal year 2021/22. For the year, the company expects organic growth of positive 13%+ and EBIT margin 5%+.Reported Earnings • May 06Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr.1.12b (up 12% from 2Q 2021). Net income: kr.175.0m (up 84% from 2Q 2021). Profit margin: 16% (up from 9.5% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 25%, compared to a 11% growth forecast for the industry in Germany.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 7 non-independent directors. Independent Director Henrik Wulff was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 09First quarter 2022 earnings: Revenues and EPS in line with analyst expectationsFirst quarter 2022 results: EPS: kr.0.08 (down from kr.0.37 in 1Q 2021). Revenue: kr.1.03b (up 1.8% from 1Q 2021). Net income: kr.20.0m (down 78% from 1Q 2021). Profit margin: 1.9% (down from 9.0% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 24%, compared to a 12% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.공시 • Feb 09Ambu A/S Revises Revenue Guidance for the Fiscal 2022Ambu A/S revised revenue guidance for the fiscal 2022. The outlook for organic growth is revised from 15% - 19% to 15% (15% or higher).공시 • Feb 05Ambu Announces FDA Clearance of Single-Use Gastroscope and Next-Generation Display UnitAmbu announced the 510(k) regulatory clearance of the Ambu® aScope™ Gastro and Ambu® aBox™ 2 in the United States. aScope Gastro is company's first sterile single-use gastroscope and includes new advanced imaging and design features in a combined solution with next-generation display and processor technology. With HD capabilities, the aBox 2 will set a new benchmark in terms of image quality and will be at the centre of company’s endoscopy ecosystem. With the launch of aScope Gastro, the company enters the gastroscopy segment, where 20 million procedures take place annually with reusable endoscope systems. The advanced technology, portability, and cost-effectiveness of company solution address the current limitations of reusable endoscopes, and it will be an attractive choice for customers looking to perform gastroscopies across a wide range of care settings (including endoscopy unit, OR, ICU, ER, ASC). Furthermore, the aScope Gastro will support healthcare systems in their efforts to reduce waiting lists and overcome staff shortages, which have been accentuated since the start of the COVID-19 pandemic. Finally, the sterile offering provides a solution to the growing cross-contamination risks, especially for vulnerable patients. Expanding Ambu’s presence in GI: Together with the launch of the aScope™ Duodeno 1.5, the aScope Gastro represents the next step in company expansion into the GI segment. They will be followed by the next generation single-use duodenoscope (aScope Duodeno 2.0), a colonoscope and a cholangioscope, giving company the most comprehensive single-use portfolio in GI.Upcoming Dividend • Dec 08Upcoming dividend of kr.0.29 per shareEligible shareholders must have bought the stock before 15 December 2021. Payment date: 17 December 2021. Payout ratio is a comfortable 30% but the company is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of German dividend payers (3.4%). Lower than average of industry peers (0.8%).Reported Earnings • Nov 12Full year 2021 earnings released: EPS kr.0.98 (vs kr.0.98 in FY 2020)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2021 results: Revenue: kr.4.01b (up 13% from FY 2020). Net income: kr.247.0m (up 2.5% from FY 2020). Profit margin: 6.2% (down from 6.8% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings.Board Change • Nov 09Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Vice-Chairman of the Board Christian Sagild was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.이익 및 매출 성장 예측DB:547A - 애널리스트 향후 추정치 및 과거 재무 데이터 (DKK Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수9/30/20287,9871,0538421,29789/30/20277,1818116381,10289/30/20266,45460551894983/31/20266,104477375847N/A12/31/20256,085544351753N/A9/30/20256,037609407791N/A6/30/20255,958359375735N/A3/31/20255,834370410733N/A12/31/20245,647326458768N/A9/30/20245,391235524813N/A6/30/20245,263450614893N/A3/31/20245,075367608902N/A12/31/20234,897238501805N/A9/30/20234,775168192518N/A6/30/20234,679-42-168217N/A3/31/20234,612-65-318119N/A12/31/20224,54595-47525N/A9/30/20224,44493-46395N/A6/30/20224,307222-401185N/A3/31/20224,152256-521107N/A12/31/20214,031176-419194N/A9/30/20214,013247-256328N/A6/30/20213,858251-187347N/A3/31/20213,832281111593N/A12/31/20203,82029056511N/A9/30/20203,567241-135295N/A6/30/20203,302146-24366N/A3/31/20203,128270-62277N/A12/31/20192,924296N/A330N/A9/30/20192,820317N/A533N/A6/30/20192,943515N/A597N/A3/31/20192,843411N/A553N/A12/31/20182,709372N/A560N/A9/30/20182,606337N/A554N/A6/30/20182,506318N/A498N/A3/31/20182,434288N/A456N/A12/31/20172,396281N/A476N/A9/30/20172,355301N/A462N/A6/30/20172,299306N/A403N/A3/31/20172,215299N/A460N/A12/31/20162,134267N/A420N/A9/30/20162,084250N/A369N/A6/30/20162,047224N/A408N/A3/31/20162,012169N/A269N/A12/31/20151,963175N/A246N/A9/30/20151,889152N/A208N/A6/30/20151,795171N/A141N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 547A 의 연간 예상 수익 증가율(23.6%)이 saving rate(1.9%)보다 높습니다.수익 vs 시장: 547A 의 연간 수익(23.6%)이 German 시장(17%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: 547A 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: 547A 의 수익(연간 10.7%)이 German 시장(연간 6.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 547A 의 수익(연간 10.7%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 547A의 자본 수익률은 3년 후 13.5%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 08:51종가2026/05/21 00:00수익2026/03/31연간 수익2025/09/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Ambu A/S는 14명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null nullABG Sundal CollierMichael HealyBerenbergSusannah LudwigBernstein11명의 분석가 더 보기
공시 • Aug 22Ambu A/S Revises Financial Guidance for the Year 2024/25Ambu A/S revised financial guidance for the year 2024/25. For the period, the company revised organic revenue growth: 12% to 14% (previously 11% to 14%) and EBIT margin b.s.i.: 13% to 15%.
공시 • Jan 10Ambu A/S Raises Financial Guidance for the Year 2024/25Ambu A/S provided financial guidance for the year 2024/25. The outlook for organic revenue growth is set to 11-14% (previously 10-13%) and for EBIT margin before special items to 13-15% (previously 12-14%).
공시 • Jan 30+ 1 more updateAmbu A/S Maintains Earnings Guidance for the Full-Year 2023/24Ambu A/S maintained earnings guidance for the Full-Year 2023/24. For the period,company expects Organic revenue growth of 7%-10%, EBIT margin before special items of 8%-10%.
공시 • Nov 09Ambu A/S Provides Earnings Guidance for the Full-Year 2023/24Ambu A/S provided earnings guidance for the full-year 2023/24 . For the year, the company expected total organic revenue growth 7-10% for the 2023/24 financial year, compared to 7.6% in 2022/23; EBIT before special items is expected to be 8-10%, compared to 6.3% in 2022/23.
공시 • Sep 01+ 1 more updateAmbu A/S Narrows Earnings Guidance for the Full-Year 2022/23Ambu A/S narrowed earnings guidance for the full-year 2022/23. For the year, the company expected organic revenue growth guidance to 6%-8%, previously 5%-8%; EBIT margin before special items: 5-6% (maintained as per 10 July 2023).
공시 • Jul 12Ambu A/S Raises Earnings Guidance for the Full-Year 2022/2023Ambu A/S raised earnings guidance for the full-year 2022/2023. For the year, company expects EBIT margin before special items to 5% - 6% (previously 3% - 5%).
공시 • Nov 07Ambu A/S announces Annual dividend, payable on December 08, 2025Ambu A/S announced Annual dividend of DKK 0.4100 per share payable on December 08, 2025, ex-date on December 04, 2025 and record date on December 05, 2025.
공시 • Oct 01Ambu A/S, Annual General Meeting, Dec 02, 2026Ambu A/S, Annual General Meeting, Dec 02, 2026.
공시 • Sep 30+ 3 more updatesAmbu A/S to Report Q1, 2026 Results on Feb 04, 2026Ambu A/S announced that they will report Q1, 2026 results on Feb 04, 2026
공시 • Aug 22Ambu A/S Revises Financial Guidance for the Year 2024/25Ambu A/S revised financial guidance for the year 2024/25. For the period, the company revised organic revenue growth: 12% to 14% (previously 11% to 14%) and EBIT margin b.s.i.: 13% to 15%.
공시 • Jan 10Ambu A/S Raises Financial Guidance for the Year 2024/25Ambu A/S provided financial guidance for the year 2024/25. The outlook for organic revenue growth is set to 11-14% (previously 10-13%) and for EBIT margin before special items to 13-15% (previously 12-14%).
공시 • Nov 08Ambu A/S Proposes DividendThe Board of Directors of Ambu A/S proposed a dividend of DKK 0.38 per share of nominally DKK 0.50 so that a dividend in the total amount of DKK 102 million be paid out of the net profit for the year, corresponding to 43% of the group's net profit, whereas the remaining part of the net profit be carried forward to next year.
Reported Earnings • Nov 06Full year 2024 earnings released: EPS: kr.0.88 (vs kr.0.65 in FY 2023)Full year 2024 results: EPS: kr.0.88 (up from kr.0.65 in FY 2023). Revenue: kr.5.39b (up 13% from FY 2023). Net income: kr.235.0m (up 40% from FY 2023). Profit margin: 4.4% (up from 3.5% in FY 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
공시 • Oct 01+ 3 more updatesAmbu A/S, Annual General Meeting, Dec 03, 2025Ambu A/S, Annual General Meeting, Dec 03, 2025.
공시 • Sep 30Ambu A/S to Report Q1, 2025 Results on Jan 30, 2025Ambu A/S announced that they will report Q1, 2025 results on Jan 30, 2025
Reported Earnings • Sep 01Third quarter 2024 earnings released: EPS: kr.0.50 (vs kr.0.19 in 3Q 2023)Third quarter 2024 results: EPS: kr.0.50 (up from kr.0.19 in 3Q 2023). Revenue: kr.1.38b (up 16% from 3Q 2023). Net income: kr.134.0m (up 163% from 3Q 2023). Profit margin: 9.7% (up from 4.3% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
Reported Earnings • May 15Second quarter 2024 earnings released: EPS: kr.0.54 (vs kr.0.06 in 2Q 2023)Second quarter 2024 results: EPS: kr.0.54 (up from kr.0.06 in 2Q 2023). Revenue: kr.1.37b (up 15% from 2Q 2023). Net income: kr.144.0m (up kr.129.0m from 2Q 2023). Profit margin: 11% (up from 1.3% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 18% per year whereas the company’s share price has fallen by 19% per year.
Reported Earnings • Jan 31First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: kr.1.25b (up 11% from 1Q 2023). Net income: kr.92.0m (up 318% from 1Q 2023). Profit margin: 7.3% (up from 1.9% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany.
공시 • Jan 30+ 1 more updateAmbu A/S Maintains Earnings Guidance for the Full-Year 2023/24Ambu A/S maintained earnings guidance for the Full-Year 2023/24. For the period,company expects Organic revenue growth of 7%-10%, EBIT margin before special items of 8%-10%.
공시 • Dec 14Ambu A/S Elects Shacey Petrovic as Vice Chair of Board of DirectorsAmbu A/S at its Annual General Meeting held on December 13, 2023, elected Shacey Petrovic as Vice Chair of the Board of Directors.
공시 • Nov 18Ambu A/S Announces Henrik Ehlers Wulff Not to Run for Re-Election for Board of DirectorsAmbu A/S at the Annual General Meeting to be held on 13 December 2023 Henrik Ehlers Wulff has decided not to run for re-election for Board of Directors.
공시 • Nov 09Ambu A/S Provides Earnings Guidance for the Full-Year 2023/24Ambu A/S provided earnings guidance for the full-year 2023/24 . For the year, the company expected total organic revenue growth 7-10% for the 2023/24 financial year, compared to 7.6% in 2022/23; EBIT before special items is expected to be 8-10%, compared to 6.3% in 2022/23.
공시 • Oct 12+ 1 more updateAmbu A/S Appoints Henrik Skak Bender as Member of the Executive Management, Effective 1 January 2024Ambu A/S has appointed Henrik Skak Bender as the company’s new Chief Financial Officer and member of the Executive Management, effective 1 January 2024. Henrik succeeds Thomas Frederik Schmidt, who will step down, effective 31 December 2023. During the past 20 years, Henrik has worked at leading international companies, such as was Audiology, Urban Partners, McKinsey & Co and A.P. Moller-Maersk. At the hearing aid company, was Audiology, he served as CFO and Head of Integration, leading the finance, IT, legal and procurement functions. Prior to that, he served as CFO at Widex, where he was responsible for developing and executing the company’s growth and transformation strategy, together with the rest of the management team. Most recently, Henrik joins from the asset management company, Urban Partners, where he serves as a member of the executive management, leading the company to grow from a Nordic player with EUR 6bn in assets under management in 2020 to a Northern European player with EUR +20bn in assets under management. At Urban Partners, Henrik held a position as Partner and COO, where he focused on driving and scaling a wide range of functions, including Investor Relations, Finance, IT and Sustainability.
공시 • Sep 30+ 4 more updatesAmbu A/S to Report Q2, 2024 Results on May 14, 2024Ambu A/S announced that they will report Q2, 2024 results on May 14, 2024
공시 • Sep 01+ 1 more updateAmbu A/S Narrows Earnings Guidance for the Full-Year 2022/23Ambu A/S narrowed earnings guidance for the full-year 2022/23. For the year, the company expected organic revenue growth guidance to 6%-8%, previously 5%-8%; EBIT margin before special items: 5-6% (maintained as per 10 July 2023).
Reported Earnings • Sep 01Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: kr.1.20b (up 5.9% from 3Q 2022). Net income: kr.51.0m (up 82% from 3Q 2022). Profit margin: 4.3% (up from 2.5% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany.
공시 • Jul 12Ambu A/S Raises Earnings Guidance for the Full-Year 2022/2023Ambu A/S raised earnings guidance for the full-year 2022/2023. For the year, company expects EBIT margin before special items to 5% - 6% (previously 3% - 5%).
Reported Earnings • May 03Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr.1.19b (up 6.0% from 2Q 2022). Net income: kr.15.0m (down 91% from 2Q 2022). Profit margin: 1.3% (down from 16% in 2Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 21% per year whereas the company’s share price has fallen by 20% per year.
Reported Earnings • Feb 08First quarter 2023 earnings released: EPS: kr.0.09 (vs kr.0.08 in 1Q 2022)First quarter 2023 results: EPS: kr.0.09 (up from kr.0.08 in 1Q 2022). Revenue: kr.1.13b (up 9.8% from 1Q 2022). Net income: kr.22.0m (up 10.0% from 1Q 2022). Profit margin: 1.9% (in line with 1Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
공시 • Feb 07Ambu A/S Provides Earnings Guidance for the Financial Year of 2022-2023Ambu A/S provided earnings guidance for the financial year of 2022-2023. For the year, the company expected organic revenue growth is 5% to 8%.
Board Change • Nov 22High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Susanne Larsson was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 16Full year 2022 earnings releasedFull year 2022 results: Revenue: kr.4.44b (up 11% from FY 2021). Net income: kr.93.0m (down 62% from FY 2021). Profit margin: 2.1% (down from 6.2% in FY 2021). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 9% per year.
공시 • Oct 01+ 3 more updatesAmbu A/S to Report Q3, 2023 Results on Aug 31, 2023Ambu A/S announced that they will report Q3, 2023 results on Aug 31, 2023
Buying Opportunity • Sep 17Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 1.1%. The fair value is estimated to be €11.74, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has declined by 21%. Revenue is forecast to grow by 26% in 2 years. Earnings is forecast to grow by 74% in the next 2 years.
Reported Earnings • Aug 26Third quarter 2022 earnings released: EPS: kr.0.11 (vs kr.0.24 in 3Q 2021)Third quarter 2022 results: EPS: kr.0.11 (down from kr.0.24 in 3Q 2021). Revenue: kr.1.13b (up 16% from 3Q 2021). Net income: kr.28.0m (down 55% from 3Q 2021). Profit margin: 2.5% (down from 6.4% in 3Q 2021). Over the next year, revenue is forecast to grow 16%, compared to a 7.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.
Valuation Update With 7 Day Price Move • Aug 06Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to €9.30, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 37x in the Medical Equipment industry in Germany. Total loss to shareholders of 33% over the past three years.
Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorated over the past weekAfter last week's 25% share price decline to €9.36, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Total loss to shareholders of 22% over the past three years.
공시 • May 20+ 1 more updateAmbu A/S Reaffirms Earnings Guidance for the Fiscal Year 2021/22Ambu A/S reaffirmed earnings guidance for the fiscal year 2021/22. For the year, the company expects organic growth of positive 13%+ and EBIT margin 5%+.
Reported Earnings • May 06Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr.1.12b (up 12% from 2Q 2021). Net income: kr.175.0m (up 84% from 2Q 2021). Profit margin: 16% (up from 9.5% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 25%, compared to a 11% growth forecast for the industry in Germany.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 7 non-independent directors. Independent Director Henrik Wulff was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 09First quarter 2022 earnings: Revenues and EPS in line with analyst expectationsFirst quarter 2022 results: EPS: kr.0.08 (down from kr.0.37 in 1Q 2021). Revenue: kr.1.03b (up 1.8% from 1Q 2021). Net income: kr.20.0m (down 78% from 1Q 2021). Profit margin: 1.9% (down from 9.0% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 24%, compared to a 12% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
공시 • Feb 09Ambu A/S Revises Revenue Guidance for the Fiscal 2022Ambu A/S revised revenue guidance for the fiscal 2022. The outlook for organic growth is revised from 15% - 19% to 15% (15% or higher).
공시 • Feb 05Ambu Announces FDA Clearance of Single-Use Gastroscope and Next-Generation Display UnitAmbu announced the 510(k) regulatory clearance of the Ambu® aScope™ Gastro and Ambu® aBox™ 2 in the United States. aScope Gastro is company's first sterile single-use gastroscope and includes new advanced imaging and design features in a combined solution with next-generation display and processor technology. With HD capabilities, the aBox 2 will set a new benchmark in terms of image quality and will be at the centre of company’s endoscopy ecosystem. With the launch of aScope Gastro, the company enters the gastroscopy segment, where 20 million procedures take place annually with reusable endoscope systems. The advanced technology, portability, and cost-effectiveness of company solution address the current limitations of reusable endoscopes, and it will be an attractive choice for customers looking to perform gastroscopies across a wide range of care settings (including endoscopy unit, OR, ICU, ER, ASC). Furthermore, the aScope Gastro will support healthcare systems in their efforts to reduce waiting lists and overcome staff shortages, which have been accentuated since the start of the COVID-19 pandemic. Finally, the sterile offering provides a solution to the growing cross-contamination risks, especially for vulnerable patients. Expanding Ambu’s presence in GI: Together with the launch of the aScope™ Duodeno 1.5, the aScope Gastro represents the next step in company expansion into the GI segment. They will be followed by the next generation single-use duodenoscope (aScope Duodeno 2.0), a colonoscope and a cholangioscope, giving company the most comprehensive single-use portfolio in GI.
Upcoming Dividend • Dec 08Upcoming dividend of kr.0.29 per shareEligible shareholders must have bought the stock before 15 December 2021. Payment date: 17 December 2021. Payout ratio is a comfortable 30% but the company is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of German dividend payers (3.4%). Lower than average of industry peers (0.8%).
Reported Earnings • Nov 12Full year 2021 earnings released: EPS kr.0.98 (vs kr.0.98 in FY 2020)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2021 results: Revenue: kr.4.01b (up 13% from FY 2020). Net income: kr.247.0m (up 2.5% from FY 2020). Profit margin: 6.2% (down from 6.8% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings.
Board Change • Nov 09Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Vice-Chairman of the Board Christian Sagild was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.